No results for ‘’
Lyka Labs Ltd
₹67.38
(3.83%)
Tue, 23 Jun 2026, 04:28 am
Health Technology
Pharmaceuticals: Other
24.5KLyka Labs Price to Sales Ratio (P/S)
| Particulars | 2005 | 2006 | 2007 | 2009 | 2010 | 2011 | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 15.43 | 0 | 29.30 | 0 | 0 | 0 | 47.67 | 0 | 0 | 0 | 0 | 0 | 9.98 | 0 | 0 | 44.83 |
| Price to book ratio | 2.16 | 1.11 | 1.03 | 0.84 | 0.67 | 0.33 | 0.30 | 0.77 | 4.05 | 3.19 | 2.61 | 1.60 | 0 | 0 | 29.17 | 7.07 | 5.14 | 3.48 |
| Price to sales ratio | 1.24 | 0.58 | 0.72 | 0.49 | 0.49 | 0.22 | 0.16 | 0.44 | 1.35 | 1.12 | 2.02 | 1.02 | 0.60 | 0.88 | 2.02 | 3.29 | 3.18 | 2.61 |
| Price to cash flow ratio | 2.75 | 0 | 0 | 0 | 0 | 0 | 0 | 0.58 | 0 | 8.99 | 67.68 | 3.51 | 0 | 24.60 | 6.75 | 0 | 0 | 0 |
| Enterprise value | 116Cr | 83.58Cr | 117Cr | 154Cr | 180Cr | 151Cr | 169Cr | 190Cr | 283Cr | 248Cr | 232Cr | 166Cr | 168Cr | 231Cr | 503Cr | 365Cr | 402Cr | 397Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 15.83 | 18.82 | 9.66 | 23.89 | 12.76 | 135.51 | 16.03 | 12.13 | 0 | 0 | 0 | 12.74 | 5.23 | 23.16 | 28.14 | 23.46 |
| Debt to equity ratio | 2.23 | 1.27 | 0.70 | 1.27 | 1.12 | 1.74 | 2.30 | 3.08 | 2.57 | 3.33 | 2.28 | 2.24 | 0 | 0 | 9.78 | 1.65 | 0.86 | 0.38 |
| Return on equity % | 0 | -30.25 | 6.75 | 0 | 2.61 | -0.55 | -1.02 | 0 | 7.75 | -13.87 | -39.63 | -12 | -423.07 | 0 | 0 | -44.95 | -4.38 | 9.33 |
Lyka Labs Ltd Price to Sales Ratio
The Lyka Labs Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Lyka Labs Ltd's valuation, profitability, and overall financial performance. Tracking the Lyka Labs Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Lyka Labs Ltd (NSE: LYKALABS, BSE: 500259) is currently trading at ₹67.38, with a market capitalization of ₹242.37Cr. As a leading company in the Health technology sector and Pharmaceuticals: other industry, monitoring the Lyka Labs Ltd Price to Sales Ratio is essential for fundamental analysis.
Lyka Labs Ltd Price to Sales Ratio Current Value
The current Lyka Labs Ltd Price to Sales Ratio stands at 2.61.
The Lyka Labs Ltd Price to Sales Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Lyka Labs Ltd Price to Sales Ratio Historical Trend
The Lyka Labs Ltd Price to Sales Ratio has shown the following historical trend:
- 2024: 2.61
- 2023: 3.18
- 2022: 3.29
- 2021: 2.02
- 2020: 0.88
The decline in Lyka Labs Ltd Price to Sales Ratio indicates improving financial efficiency or better earnings growth.
What Lyka Labs Ltd Price to Sales Ratio Indicates for Investors
The Lyka Labs Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/S ratio helps evaluate valuation relative to company revenue.
Lyka Labs Ltd Price to Sales Ratio Analysis Summary
The Lyka Labs Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Lyka Labs Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Lyka Labs Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.